Browsing Tag: Biosimilar Semaglutide

Key Highlights:  Implications:  Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...